Northwest & Ethical Investments’s Pacira BioSciences PCRX Stock Holding History

Northwest & Ethical Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-70,325	Closed	-$2.16M	–	397
2023 Q3	$2.16M	Hold	70,325	–	–	0.07%	228
2023 Q2	$2.82M	Sell	70,325 -34,606	-33%	-$1.43M	0.09%	223
2023 Q1	$4.28M	Sell	104,931 -1,656	-2%	-$65.9K	0.14%	185
2022 Q4	$4.12M	Buy	106,587 +11,193	+12%	+$545K	0.14%	189
2022 Q3	$5.07M	Hold	95,394	–	–	0.2%	150
2022 Q2	$5.56M	Buy	95,394 +5,092	+6%	+$334K	0.21%	141
2022 Q1	$6.89M	Buy	90,302 +54,720	+154%	+$3.65M	0.22%	126
2021 Q4	$2.14M	Buy	+35,582	New	+$1.96M	0.06%	235

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Northwest & Ethical Investments's PCRX Position: Q4 2023 in Review

Northwest & Ethical Investments sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 70,325 shares — an estimated $2.16M sold.

Northwest & Ethical Investments first reported a position in PCRX in Q4 2021 and held it in 8 quarters. The position peaked at $6.89M in Q1 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Northwest & Ethical Investments reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Northwest & Ethical Investments sold 70,325 Pacira BioSciences shares in Q4 2023, an estimated $2.16M.
Northwest & Ethical Investments first reported a position in Pacira BioSciences in Q4 2021 and held it in 8 quarters.
Northwest & Ethical Investments's Pacira BioSciences position peaked at $6.89M in Q1 2022.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Northwest & Ethical Investments's 13F filing for Q4 2023, filed 9 Jul 2025.